[Adverse effects of combining polyethylene glycol interferon with ribavilin on hepatitis C patients].
Si
Chong-wen
CW
First Hospital, Peking University, Beijing 100034, China.
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005221:Fatigue / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D010146:Pain / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000737:chemistry; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin